Table 3.
Baseline characteristics of cirrhotic patients according to late HCC development: univariate and multivariate analysis (n = 306).
| Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|
| HCC | |||||
| Parameter | Yes (n = 20) | No (n = 286) | p | O.R. [95% C.I.] | p |
| Age (yrs), median [IQR] | 70 [68.2–75] | 67 [59.5–72] | 0.026 | ||
| Sex, n (%) | 0.050 | ||||
| M/F | 15 (75)/5 (25) | 150 (52.4)/136 (47.6) | |||
| BMI, median [IQR] | 25 [23.2–26.7] | 26.2 [24.7–28.4] | 0.026 | 0.712 [0.537–0.943] | 0.018 |
| Smoke, n (%) | 2 (10) | 0 (-) | 0.000 | ||
| Potus, n (%) | 2 (10) | 0 (-) | 0.000 | ||
| Diabetes, n (%) | 9 (45) | 50 (17.5) | 0.003 | 0.180 [0.045–0.713] | 0.015 |
| Metabolic syndrome, n (%) | 3 (15) | 19 (6.6) | 0.162 | ||
| Liver stiffness (kPa), median [IQR] | 26.5 [18–44.5] | 20.4 [16–28.7] | 0.028 | 1.070 [1.020–1.122] | 0.006 |
| Duration of therapy (weeks), median [IQR] | 12 [12–12] | 12 [12–24] | 0.007 | ||
| Platelets, median [IQR] | |||||
| T0 | 75,000 [48,000–109,500] | 115,000 [80,000–166,000] | 0.001 | 0.975 [0.954–0.996] | 0.019 |
| SVR | n.a. | n.a. | n.a. | ||
| Genotype, n (%) | 0.095 | ||||
| 1 | 15 (75) | 228 (79.7) | |||
| 2 | 3 (15) | 47 (16.4) | |||
| 3 | 1 (5) | 10 (3.5) | 0.007 [0.000–0.417] | 0.017 | |
| 4 | 1 (5) | 1 (0.3) | 0.003 [0.000–0.280] | 0.012 | |
| Number of lesions, n (%) | 0.000 | ||||
| 0 | 0 (-) | 286 (100) | |||
| 1 | 15 (75) | 0 (-) | |||
| ≥2 | 5 (25) | 0 (-) | |||
| Portal invasion, n (%) | 4 (11.4) | 0 (-) | 0.000 | ||
| Bright liver, n (%) | 1 (5) | 21 (16.8) | 0.172 | ||
| Child–Pugh Score T0, n (%) | 0.000 | ||||
| A | 15 (75) | 274 (95.8) | |||
| B | 5 (25) | 12 (4.2) | |||
| Child–Pugh Score SVR12, n (%) | 0.000 | ||||
| A | 17 (85) | 281 (98.3) | |||
| B | 3 (15) | 5 (1.7) | |||
| Therapy, n (%) | 0.000 | ||||
| Sofosbuvir/Ribavirin | 16 (80) | 64 (22.4) | |||
| Sofosbuvir/Ledipasvir | 0 (-) | 69 (24.1) | |||
| Sofosbuvir/Daclatasvir | 1 (5) | 22 (7.7) | |||
| Sofosbuvir/Simeprevir | 1 (5) | 49 (17.1) | |||
| 3D | 2 (10) | 82 (28.7) | |||
Data are expressed ad either the number and percentage or median and interquartile range (IQR) BMI, body mass index; SVR, sustained virological response has been observed at all timepoints 12–14–48 weeks.